13,180 views |
21 hours ago
How Will Covid-19 Vaccines Be Priced Post-Pandemic?
Pfizer’s CFO, Frank D’Amelio, has raised eyebrows with recent comments about the future pricing of Pfizer’s Covid-19 vaccine.
ABOUTRead MoreRead Less
I was the president of Pfizer Global Research and Development in 2007 where I managed more than 13,000 scientists and professionals in the United States, Europe, and Asia. I've received numerous awards including an Honorary Doctor of Science degree
...I was the president of Pfizer Global Research and Development in 2007 where I managed more than 13,000 scientists and professionals in the United States, Europe, and Asia. I've received numerous awards including an Honorary Doctor of Science degree from the University of New Hampshire. I am also the author of "Drug Truths: Dispelling The Myths Of R&D" and the recently published Devalued And Distrusted: Can The Pharmaceutical Industry Restore Its Broken Image?" I am also a senior partner at PureTech Health.
LATESTARCHIVE
13,727 views |
Mar 12, 2021
What Else Can Go Wrong With AstraZeneca’s Covid-19 Vaccine?
If as the NYT reports, there truly are countries who would like access to this vaccine, why not offer the opportunity to acquire the AstraZeneca/Oxford vaccine to the World Health Organization, which has strongly advocated for more widespread access of Covid-19 vaccines to other parts of the world?
2,496 views |
Feb 25, 2021
Pfizer Should Be Wary About Covid-19 Vaccine Price Hikes
In early July of 2020, Elisabeth Rosenthal published an op-ed in the New York Times warning about the biopharmaceutical industry trying to profit outrageously from a successful Covid-19 vaccine.
2,700 views |
Feb 24, 2021
Biopharma Closely Watching Biden’s Pick For The Next FDA Commissioner – With Biogen Having The Most At Stake
If approved, biopharmaceutical critics will accuse the F.D.A. of being too closely aligned with industry. If rejected, the F.D.A will be attacked by patients and advocacy groups as preventing access to a much needed new medicine.
5,307 views |
Feb 3, 2021
What Congresswoman Porter Misses In Analysis Of Biopharma M&A
Unfortunately, the “blockbuster report” from Congresswoman Porter’s Office is instead a tired screed which does not add to the public’s understanding and appreciation of the biopharmaceutical industry.
March 2021 (2)
February 2021 (3)
January 2021 (3)
December 2020 (1)
November 2020 (1)
October 2020 (2)
September 2020 (2)
August 2020 (1)
July 2020 (2)
June 2020 (2)
May 2020 (2)
January 2020 (4)
October 2019 (3)
September 2019 (2)
August 2019 (4)
July 2019 (2)
June 2019 (5)
May 2019 (2)
April 2019 (2)
March 2019 (3)
February 2019 (2)
January 2019 (5)
December 2018 (2)
November 2018 (2)
October 2018 (3)
September 2018 (3)
August 2018 (1)
July 2018 (1)
June 2018 (5)
May 2018 (5)
April 2018 (1)
March 2018 (5)
February 2018 (1)
January 2018 (2)
December 2017 (2)
November 2017 (2)
October 2017 (2)
August 2017 (2)
July 2017 (3)
June 2017 (5)
April 2017 (5)
March 2017 (2)
February 2017 (3)
January 2017 (5)
December 2016 (1)
November 2016 (5)
October 2016 (5)
September 2016 (5)
August 2016 (5)
June 2016 (5)
May 2016 (4)
April 2016 (3)
March 2016 (5)
February 2016 (5)
January 2016 (5)
December 2015 (5)
November 2015 (5)
October 2015 (5)
September 2015 (6)
August 2015 (6)
July 2015 (5)
June 2015 (5)
May 2015 (5)
April 2015 (5)
March 2015 (5)
February 2015 (6)
January 2015 (6)
December 2014 (5)
November 2014 (6)
October 2014 (5)
September 2014 (5)
August 2014 (5)
July 2014 (5)
June 2014 (5)
May 2014 (7)
April 2014 (6)
March 2014 (5)
February 2014 (5)
January 2014 (6)
December 2013 (5)
November 2013 (6)
October 2013 (6)
September 2013 (5)
August 2013 (6)
July 2013 (6)
June 2013 (5)
May 2013 (6)
April 2013 (7)
March 2013 (6)
February 2013 (6)
January 2013 (7)
December 2012 (5)
November 2012 (5)
October 2012 (6)
September 2012 (5)
August 2012 (4)
July 2012 (5)
June 2012 (5)
May 2012 (6)
April 2012 (5)
March 2012 (5)
February 2012 (4)